Lab Company Wants Permission to Import Controlled Drugs
Published Date: 11/26/2025
Notice
Summary
VHG Labs, also known as LGC Standards, wants to become an official importer of certain controlled substances. This means they’ll be allowed to bring in specific drugs for research or testing. People who make or use these substances can comment or ask for a hearing by December 26, 2025, so act fast if you have thoughts or concerns!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Application to Import Listed Schedule I Substances
On September 30, 2025, VHG Labs DBA LGC Standards (Manchester, New Hampshire) applied to be registered to import specific Schedule I controlled substances (for example, 3-methylmethcathinone, drug code 1259, and Zipeprol, drug code 9873, plus numerous listed fentanyl analogs such as drug codes 9817–9863). The company says it plans to import those substances for distribution for analytical testing purposes only.
Import Authorization Excludes Finished Dosage Forms
The registration, if granted, will authorize importation of the listed drug codes only for analytical testing and will not authorize import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. Approval will be limited to activities consistent with 21 U.S.C. 952(a)(2).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2025-21180, Importer of Controlled Substances Application: NSI Lab Solutions, LLC.
NSI Lab Solutions, LLC wants to become an official importer of certain controlled substances, including some strong drugs like 3-FMC and Cathinone. This affects companies involved in drug manufacturing and import, who can comment or request a hearing by December 26, 2025. No direct money changes yet, but this move could impact the drug supply chain and regulatory oversight.
Next: 2025-21182, Bulk Manufacturer of Controlled Substances Application: Groff NA Hemplex LLC
Groff NA Hemplex LLC wants to become a big-time maker of marijuana and related substances for research. If you’re a registered manufacturer or interested party, you can share your thoughts or ask for a hearing by January 26, 2026. This move could boost research supply but doesn’t change prices or public access.